TY - JOUR T1 - Oxygen provision to severely ill COVID-19 patients at the peak of the 2020 pandemic in a Swedish district hospital JF - medRxiv DO - 10.1101/2021.03.11.21253350 SP - 2021.03.11.21253350 AU - Anna Hvarfner AU - Ahmed Al-Djaber AU - Hampus Ekström AU - Malin Enarsson AU - Markus Castegren AU - Tim Baker AU - Carl Otto Schell Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/30/2021.03.11.21253350.abstract N2 - Oxygen is a low-cost and life-saving therapy for patients with COVID-19. Yet, it is a limited resource in many hospitals in low income countries and in the 2020 pandemic even hospitals in richer countries reported oxygen shortages. An accurate understanding of oxygen requirements is needed for capacity planning. The World Health Organization estimates the average flow-rate of oxygen to severe COVID-19-patients to be 10 l/min. However, there is a lack of empirical data about the oxygen provision to patients. This study aimed to estimate the oxygen provision to COVID-19 patients with severe disease in a Swedish district hospital.A retrospective, medical records-based cohort study was conducted in March to May 2020 in a Swedish district hospital. All adult patients with severe COVID-19 – those who received oxygen in the ward and had no ICU-admission during their hospital stay – were included. Data were collected on the oxygen flow-rates provided to the patients throughout their hospital stay, and summary measures of oxygen provision calculated.One-hundred and twenty six patients were included, median age was 70 years and 43% were female. On admission, 27% had a peripheral oxygen saturation of ≤91% and 54% had a respiratory rate of ≥25/min. The mean oxygen flow-rate to patients while receiving oxygen therapy was 3.0 l/min (SD 2.9) and the mean total volume of oxygen provided per patient admission was 16,000 l (SD 23,000).In conclusion, the provision of oxygen to severely ill COVID-19-patients was lower than previously estimated. Further research is required before global estimates are adjusted.Competing Interest StatementDr. Baker reports a grant and personal fees from Wellcome Trust, and personal fees from UNICEF and the World Bank, all outside the submitted work.Funding StatementThis work was supported by the Regional Research Council in Mid Sweden grant number RFR-931271. The funders had no role in the design of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical Review Board in Lund, reference number 2020-04012. As the study did not alter patient care and data were anonymised before analysis, individual patient consent was waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data can be provided after contact with and provision of an approved research plan to the corresponding author. ER -